Head to Head Analysis: Profound Medical (NASDAQ:PROF) & Curaleaf (OTCMKTS:CURLF)

Curaleaf (OTCMKTS:CURLF) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

0.0% of Curaleaf shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 1.5% of Profound Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Curaleaf and Profound Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curaleaf	$1.27 billion	1.56	-$231.07 million	($0.04)	-211.75
Profound Medical	$23.63 million	11.74	-$42.57 million	($0.93)	-8.14

Profound Medical has lower revenue, but higher earnings than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Curaleaf and Profound Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-0.76%	0.43%	0.13%
Profound Medical	-137.51%	-59.57%	-47.87%

Volatility and Risk

Curaleaf has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Curaleaf and Profound Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	1	2	1	3.00
Profound Medical	1	0	1	1	2.67

Curaleaf presently has a consensus price target of $6.00, indicating a potential downside of 29.16%. Profound Medical has a consensus price target of $11.50, indicating a potential upside of 51.92%. Given Profound Medical’s higher possible upside, analysts plainly believe Profound Medical is more favorable than Curaleaf.

Summary

Curaleaf beats Profound Medical on 8 of the 14 factors compared between the two stocks.

About Curaleaf

Curaleaf Holdings, Inc. is a cannabis company that cultivates, processes and sells cannabis products for medical and adult-use markets. Its products include cannabis flower, pre-rolls, concentrates, vapes, edibles, tinctures and topical products, sold under brands including Curaleaf, Select and Grassroots. The company operates across multiple U.S. markets through cultivation and processing facilities, wholesale operations and retail dispensaries. Through Curaleaf International, it also serves medical cannabis markets in Europe and other international markets.

About Profound Medical

Profound Medical Corp. is a medical-technology company focused on developing and commercializing minimally invasive, incision-free treatments for prostate disease. The company’s flagship platform, TULSA-PRO, combines magnetic resonance imaging (MRI) with robotic-controlled transurethral ultrasound to ablate targeted prostate tissue while enabling physicians to monitor treatment in real time. TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia.